Pidonex400 mg

Pidonex is a synthetic immunostimulant (immunomodulator) used as follows:

Established/guideline-supported use

• Adjunctive/prophylactic reduction of recurrent respiratory tract infections (RRTIs): Pidonex is used to reduce the frequency, duration, and severity of recurrent upper and lower respiratory tract infections (e.g., recurrent colds, pharyngitis, tonsillitis, otitis media, bronchitis), particularly in children with a history of frequent infections. Several randomized trials and a multi-society pediatric consensus statement support its use as a preventive/adjunctive immunomodulatory strategy in this setting.

Adjunct use requiring combination therapy

• Pidonex is sometimes used alongside standard antibiotic or symptomatic treatment during an acute respiratory infection, or as add-on therapy in patients also receiving other supportive care, with the aim of shortening illness duration and lowering relapse/recurrence rates — it is not a treatment for the acute infection itself.

Evidence caveat

Note: The evidence base for Pidonex is stronger and use is more established in some countries (e.g., parts of Europe and Asia) than in others; Pidonex is not approved by the US FDA and is not a substitute for vaccination, antibiotics when indicated, or other standard-of-care infection treatment/prevention measures.

Each dose of Pidotimod contains Pidotimod as the active pharmaceutical ingredient. Pidotimod is available in oral formulations such as:

• Oral solution/syrup (commonly 400 mg per single-dose sachet or per measured volume)
• Oral dispersible sachets/granules
• Film-coated tablets (commonly 400 mg or 800 mg strengths, by region)

Exact strengths and pack sizes vary by manufacturer and country; refer to the specific product label.

Pidonex is a synthetic dipeptide-like immunostimulant molecule that acts on both innate and adaptive immune responses. It is used mainly to reduce the frequency and severity of recurrent respiratory tract infections, particularly in children who experience frequent colds, tonsillitis, otitis media, or bronchitis.

Pidonex is not an antibiotic and does not directly kill or inhibit pathogens; instead, it modulates the patient's own immune system to help the body respond more effectively to, and recover more quickly from, respiratory infections, and to reduce how often they recur. It is typically given as a preventive/adjunctive course rather than as treatment for an acute infection in progress.

Immunostimulant / Immunomodulator — Pidonex is classified as a synthetic immune-response modifier used in the prevention of recurrent respiratory infections.

Mechanism of action

Pidotimod acts on multiple components of the innate and adaptive immune system rather than on the infecting organism directly. Proposed and demonstrated effects include:

• Promoting maturation and antigen-presenting function of dendritic cells.
• Enhancing phagocytic and chemotactic activity of neutrophils and macrophages.
• Increasing natural killer (NK) cell activity.
• Favoring a balanced Th1-type cytokine response and modulating pro-inflammatory cytokine release.
• Promoting mucosal immunity, including secretory IgA production at respiratory mucosal surfaces.

Pharmacokinetics

Pidotimod is absorbed after oral administration, with peak plasma concentrations typically reached within a few hours; it undergoes limited metabolism and is eliminated predominantly via the kidneys. It does not have direct antimicrobial or antiviral activity.

Pidonex is given by mouth. Oral solution/sachet formulations can be taken directly or mixed with a small amount of water; tablets should be swallowed with water. Pidonex may be taken with or without food, according to product labeling. Doses should be spaced evenly if given more than once daily, and courses should be completed as prescribed even if symptoms are not currently present, since it is often used preventively.

No extensively documented, clinically significant pharmacokinetic drug-drug interactions have been well established for Pidonex. Because Pidonex works by modulating immune function, caution and physician guidance are advised when it is used together with:

• Immunosuppressive medicines (e.g., systemic corticosteroids, other immunosuppressants) — theoretical potential for reduced immunostimulant effect or altered immune response; use only under medical supervision.
• Other immunostimulant products — concurrent use is generally unnecessary and should be guided by a physician.

Always inform the prescribing physician of all other medicines, supplements, and vaccines being used.

Pidonex is generally well tolerated. Reported adverse effects include:

Common

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, abdominal discomfort.

Uncommon/rare

• Skin reactions: rash, urticaria, itching.
• Hypersensitivity reactions, including rare reports of more severe allergic reactions.
• Headache or mild dizziness.

Patients should seek medical attention if signs of an allergic reaction (swelling, difficulty breathing, severe rash) occur.

Data on the use of Pidonex during pregnancy and breastfeeding are limited. As a precaution, Pidonex should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only under medical supervision. Similarly, use during breastfeeding should be avoided unless a physician determines it is necessary, since it is not established whether Pidonex passes into breast milk. Pregnant or breastfeeding individuals should consult a physician before use.

Pidonex should be used with the following precautions:

• Pidonex is an adjunctive/preventive immunomodulator, not a treatment for an acute infection in progress, and is not a substitute for antibiotics when a bacterial infection requires them, nor for routine childhood vaccination — standard-of-care diagnosis and treatment should not be delayed or replaced.
• Evidence supporting Pidonex is more extensive in some regions/populations than others; expected benefit (reduction in frequency/severity of recurrent infections) should be discussed with a physician rather than assumed for every patient.
• Use with caution in patients with known autoimmune disease or those on immunosuppressive therapy, given its immune-modulating activity (see Interactions).
• Discontinue and seek medical advice if signs of hypersensitivity occur (see Side Effects).
• Safety in pregnancy and lactation is not well established (see Pregnancy and Lactation).

Reports of Pidonex overdose are limited, and significant toxicity has not been well characterized. In case of a suspected overdose of Pidonex, seek immediate medical attention or contact a poison control center/emergency services. Management would generally involve supportive and symptomatic care, as directed by a healthcare professional; no specific antidote is established.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal/hepatic impairment

Specific dose-adjustment data for Pidonex in renal or hepatic impairment are limited; use with caution and under medical supervision in these populations, as Pidonex is renally eliminated.

Elderly

Limited specific data exist for elderly patients; Pidonex is used at standard adult doses under medical supervision, with attention to any comorbid conditions.

Children

See Pediatric Uses.

Pregnancy and lactation

See Pregnancy and Lactation.

Pidonex is typically given in cyclic courses rather than continuously — for example, a course of about 15 days of daily dosing, repeated over 2–3 monthly cycles, or an extended course of several weeks, depending on the product and the treating physician's protocol. The exact duration should be individualized by the prescriber based on the frequency and severity of the patient's recurrent infections and response to therapy; Pidonex should not be continued indefinitely without medical review.

Immunostimulants; Immunomodulatory agents

Pidotimod enhances both innate and adaptive immune responses: it promotes dendritic cell maturation and antigen presentation, increases phagocytic activity of neutrophils and macrophages, boosts natural killer (NK) cell cytotoxicity, favors a balanced Th1-oriented cytokine profile, and supports mucosal defenses including secretory IgA. Through these combined effects, Pidotimod helps the immune system respond more effectively to respiratory pathogens and reduces the frequency of recurrent infections, without acting as a direct antimicrobial agent.

Pidonex is used primarily in children with a history of recurrent respiratory tract infections (e.g., frequent colds, tonsillitis, otitis media, bronchitis), typically from around 3 years of age and older, according to most local product labels, given as oral solution or sachet at a dose of 400 mg once or twice daily in cyclic courses (see Dosage and Administration).

Safety and efficacy in infants and very young children (below the labeled minimum age) have not been well established, and Pidonex should only be used in this age group under direct physician guidance. As with adults, Pidonex in children is adjunctive/preventive and does not replace vaccination or standard treatment of an active infection.